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Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However,
there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of
bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers,
while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents,
platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to
determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator
mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in
advanced bladder cancer.
1. Introduction
Bladder urothelial cancer is the 4th most common cancer in
males and 9th in females and a major cause of morbidity and
mortality worldwide. In the United States, approximately
70,530 individuals were diagnosed with bladder cancer in
2010 and 14,680 died from it [1]. Most bladder cancers in the
developed world are of urothelial origin (transitional cell),
arising from the epithelial lining. Bladder cancers are broadly
classified as noninvasive or invasive (muscle-invasive and
metastatic) cancers. The noninvasive and invasive subtypes
are thought to arise from distinct biological pathways [2].
About 70 to 80% of newly diagnosed bladder cancers are
noninvasive. The initial treatment of noninvasive cancer in-
volves a complete transurethral resection followed by adju-
vant intravesical therapy [3]. As many as 70% of noninvasive
cancers recur, necessitating life-long surveillance, and up to
25% will progress to more advanced disease [4, 5].
For patients with muscle-invasive, nonmetastatic disease,
radical cystectomy with bilateral pelvic lymph node dissec-
tion remains the mainstay of treatment. Recurrence can be
frequent even after surgery. For example, about 50% of pa-
tients with deep, muscle-invasive disease will develop meta-
static disease even after surgery [6]. Thus, systemic platinum-
based chemotherapy, either in a neoadjuvant or adjuvant set-
ting, is considered a component of the standard care for
this disease. Metastatic disease is usually treated with chem-
otherapy, but the median survival even with the best chemo-
therapy is often only about 14 months [7].
Improving survival outcomes in advanced bladder cancer
will require moving beyond conventional histopathologic
evaluation such as stage and grade. Molecular biomarkers
have the potential to more accurately determine prognosis
and assign patients to appropriate treatments. Such biomark-
ers are already being used in other solid tumors such as
breast, colon, and lung. For example, high expression of the
ERCC1 gene is prognostic of improved survival and predic-
tive of reduced response to platinum-based therapy in non-
small cell cancer (NSCLC) [8]. Many promising biomarkers
are now being evaluated for bladder cancer, offering the po-
tential of improving clinical outcomes. As our understanding
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of the molecular pathways in bladder cancer improves, more
personalized therapies can be delivered that are potentially
more active and hopefully less toxic. In this paper, we will
review the current chemotherapeutic treatments for ad-
vanced disease, highlight the potential role of biomarkers,
and remark on the future direction of bladder cancer care.
2. Treatment of Muscle-Invasive
Bladder Cancer
The current standard treatment in the United States for
muscle-invasive bladder cancer is radical cystectomy with
bilateral pelvic lymph node dissection. These patients often
develop metastatic disease despite aggressive surgical inter-
vention. In organ-confined pT2 disease, the 5-year survival
rate is approximately 68% [9]. Patients with more deeply in-
vasive tumors have lower five-year survival rates of 30 to
50% [10]. Relapse is due to the presence of occult micro-
metastases.
2.1. Neoadjuvant Therapy. The rationale for neoadjuvant
chemotherapy prior to cystectomy is to treat micrometastatic
disease that is present at diagnosis. It also helps downstage
the tumor and increases the potential for complete resection
of tumor. Furthermore, neoadjuvant chemotherapy allows
delivery of systemic therapy through intact blood vessels and
can be better tolerated before the patient is debilitated by
surgery. There is level I evidence with two randomized trials
to support the use of neoadjuvant chemotherapy [11, 12].
The largest neoadjuvant chemotherapy trial was conducted
by the Medical Research Council/European Organisation for
Research and Treatment of Cancer. In this phase III trial, 976
patients with high-grade T2-T4a, N0-NX, M0 bladder can-
cer were randomly assigned to three cycles of neoadjuvant
chemotherapy (CMV: cisplatin, methotrexate, and vinblas-
tine, n = 491) or no chemotherapy (n = 485) then followed
by institution’s choice of therapy with radical cystectomy
and/or radiation therapy [11]. At three years, the pathologic
complete response (pCR) in the neoadjuvant groupwas 33%.
Although there was a 5.5% survival benefit at three years
(55.5 for chemotherapy versus 50% for no chemotherapy), it
did not reach statistical significance. At eight-year followup,
results showed a statistically significant 16% reduction in the
risk of death, corresponding to an increase in 10-year sur-
vival from 30 to 36% after neoadjuvant chemotherapy [13].
A US Intergroup trial (INT 0080) randomized 307 pa0
tients with stage T2-4, N0, M0 bladder cancer to three cycles
of neoadjuvant methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) or no chemotherapy followed by cystec-
tomy [12]. The trial took 13 years to accrue. At a median
followup of 8.7 years, pCR with MVAC was higher (38 versus
15%). Patients treated with MVAC showed an improvement
in median overall survival (77 versus 46 months, P = 0.06)
and five-year overall survival (57 versus 43%, P = 0.06) that
were of borderline statistical significance.
The benefit of neoadjuvant chemotherapy was confirmed
by a meta-analysis of 11 randomized trials with 3005 pa-
tients. It was found that those who received neoadjuvant
platinum-based combination chemotherapy compared to
local therapy alone had a 14% reduction in the risk of death
[14]. This was equivalent to a 5% absolute improvement in
overall survival from 45 to 50% at 5 years (P = 0.003).
There was also a significant disease-free survival benefit (P <
0.0001), equivalent to a 9% absolute improvement at 5 years.
Even though CMV and MVAC were used in the above-
mentioned prospective trials, the gemcitabine and cisplatin
(GC) combination is commonly used in the neoadjuvant set-
ting. There is no randomized trial supporting the use of the
GC regimen in this setting. Clinicians mainly extrapolated
the data in the metastatic setting showing similar efficacy but
better tolerability with the GC regimen compared to MVAC.
Neoadjuvant cisplatin-based chemotherapy is not widely
used in practice even though there is level I evidence indi-
cating a significant survival advantage for patients with mus-
cle-invasive bladder cancer [15]. An analysis of 7,161 patients
with stage III bladder cancer from the National Cancer Data-
base between 1998 to 2003 revealed that perioperative chem-
otherapy was administered to 11.6% of patients with stage
III bladder transitional cell carcinoma with 10.4% receiving
adjuvant chemotherapy and 1.2% receiving neoadjuvant
chemotherapy [16]. A more recent analysis from the same
database between 2003 and 2007 showed a slight increase in
the use of neoadjuvant chemotherapy (up to 13% of patients
in 2007) [17]. One major concern is the potential for disease
progression due to delayed definitive treatment in patients
who do not respond to neoadjuvant chemotherapy. There is
a critical need to identify those who will respond favorably to
neoadjuvant chemotherapy.
2.2. Adjuvant Therapy. The postoperative adjuvant approach
has several advantages. It allows for selection of patients at
highest risk for surgical failure based on accurate pathologic
staging, avoids delay in potentially curative surgery especially
in nonresponders to chemotherapy, and prevents overtreat-
ing patients who may have a reasonable outcome from sur-
gery alone. The drawbacks include difficulty in administering
chemotherapy postoperatively as a result of declines in per-
formance status or development of complications and delays
in treating occult metastatic disease.
The results from the adjuvant trials have been conflicting
and difficult to interpret. Two small trials have shown a sig-
nificant difference in favor of adjuvant chemotherapy. One
trial randomized 91 patients with pT3-T4a or node-positive
bladder cancer to four cycles of adjuvant chemotherapy or to
observation after radical cystectomy [18]. The chemotherapy
regimen employed was cisplatin, cyclophosphamide, and do-
xorubicin. There was a significant improvement in median
survival in the adjuvant group (4.3 versus 2.4 years, P =
0.0062) and percentage free of progression (70 versus 46%,
P = 0.01) at three years compared to observation. The three-
year overall survival in patients was not statistically signifi-
cant though. A German trial randomized 49 similarly high-
risk patients (pT3b, pT4a, and/or positive pelvic lymph
nodes) to MVAC, MVEC (methotrexate, vinblastine, epiru-
bicin, and cisplatin), or observation [19]. It was terminated
early when an interim analysis showed significant improve-
ment in three-year progression-free survival (PFS) (63%
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versus 13%, P = 0.002). Ten-year survival data from this trial
still favored adjuvant chemotherapy over surgery alone [20].
Of note, most patients randomly assigned to observation
after cystectomy were not given chemotherapy at the time of
relapse.
Other trials revealed no benefit with adjuvant chem-
otherapy. A Swiss trial randomized 77 patients with muscle-
invasive (pT2), nonmetastatic bladder cancer to observation
or 3 cycles of cisplatin. There was no significant difference in
the overall survival at 5 years between the treatment and con-
trol group (57 versus 54%) [21].
The positive trials were criticized for having major defi-
ciencies including small sample size, early stopping of patient
entry, inappropriate statistical analyses, and poor reporting
of results [22]. A meta-analysis based on 491 patients from
six trials reported an absolute improvement in survival of 9%
at 3 years [23]. It did acknowledge that the results were drawn
from limited data and, therefore, was insufficient to base
reliable treatment decisions. Many large cooperative group
trials were designed to answer the adjuvant chemotherapy
question but have been terminated prematurely due to prob-
lems with accrual. A recent large retrospective cohort study
consisting of 3,947 patients from 11 centers demonstrated a
significant survival benefit with adjuvant chemotherapy in
patients at the highest risk of disease progression, such as
those with advanced pathologic stage and nodal involvement
[24]. In the 20% of patients with the highest risk disease, the
median survival was 25 weeks for those receiving adjuvant
chemotherapy and 19.2 weeks for those who did not. As of
now, adjuvant chemotherapy is commonly used in patients
with pT3-T4 or node-positive disease who have not received
neoadjuvant chemotherapy.
3. Treatment of Metastatic Bladder Cancer
The standard treatment for patients with metastatic bladder
cancer is systemic chemotherapy. Although bladder cancer is
a chemosensitive tumor, the median survival with chemo-
therapy is only around 14 months. The five-year survival rate
remains poor at about 15% [7]. Cisplatin-based combination
therapy is considered first-line based on a prospective ran-
domized trial that compared cisplatin alone to MVAC in
269 patients [25]. Patients treated withMVAC had significant
improvement in response rate (39 versus 12%), PFS (10
versus 4.3 months), and overall survival (12.5 versus 8.2
months). Toxicity is a major concern with the MVAC regi-
men, particularly leukopenia, febrile neutropenia, mucositis,
and nausea/vomiting. Only 24% of the patients received
full-dose MVAC without dosage modifications. Five patients
(4%) in the MVAC group plus 2 patients who were switched
over to the MVAC regimen died from treatment-related tox-
icity.
In the search for a less toxic yet still effective regimen, a
randomized phase III trial of 405 patients compared GC to
MVAC [26]. The overall response rate (49 versus 46%), time
to progression (7.4 versus 7.4 months), and median survival
(13.8 versus 14.8 months) were similar for both regimens.
Patients treated with GC were more likely to complete treat-
ment with fewer dose adjustments. They had experienced less
grade 3 or 4 neutropenia, neutropenic sepsis, and mucositis.
An updated analysis showed similar 5-year overall survival
rates of 13.0% for GC and 15.3% for MVAC [7]. Although
the trial was not designed as an equivalence trial, GC has
been adopted by many as the standard first-line treatment
based on similar efficacy and lesser toxicity.
Another randomized phase III trial assigned 263 patients
to high-dose-intensity MVAC (2-week cycles) with granu-
locyte colony-stimulating factor (G-CSF) versus standard
MVAC (4-week cycles) to see if overall survival can be im-
proved [27]. High-dose-intensity MVAC had significantly
improved complete response (21 versus 9%), overall res-
ponse (62 versus 50%), and the median PFS time (9.1 versus
8.2 months), but there was no difference in overall survival.
Toxicity was less with high-dose-intensity MVAC which was
attributed to the use of G-CSF. In a subsequent seven-year
update, there was a significant survival advantage at 5 years
with high-dose-intensity MVAC (21.8 versus 13.5%) [28].
This regimen is becomingmore popular because of improved
outcomes, shorter duration, and less toxicity compared to
standard MVAC.
4. Biomarkers for Personalized Chemotherapy
Currently, chemotherapy for bladder cancer is taking the ap-
proach of one formula for all. Most patients presently receive
a platinum-based regimen, usually GC. However, only about
half of the bladder cancers will respond to chemotherapy.
Extensive research is ongoing to better understand the bio-
logy of the disease process in order to improve clinical out-
comes. Conventional prognostic factors such as the grade
and stage of the tumor and tools like nomograms are useful
in predicting the outcomes associated with surgery and the
risk of recurrence but are inadequate in predicting response
to chemotherapy [29, 30]. Biomarkers have the potential not
only to further identify high-risk bladder cancer patients, but
also to help select therapy for those who will benefit most
from it. A personalized approach to chemotherapy has the
potential to reduce toxicity and improve clinical outcomes
(Table 1).
4.1. Single Gene Markers
4.1.1. p53. p53 is the most studied biomarker in bladder
cancer and many other cancer types. It plays a critical role in
the regulation of cell cycle and is also involved in DNA da-
mage and repair, cell cycle arrest, and apoptosis [31]. Altera-
tion in the p53 leads to a loss of its tumor suppressor function
and is thought to be a key event in carcinogenesis. It has been
reported that overexpression of p53 in the nucleus, as detect-
ed by immunohistochemistry, was associated with increased
risk of recurrence and death in bladder cancer [32, 33].
However, a meta-analysis of 117 studies comprising of 10,026
patients showed that changes in p53 were only weak-ly
predictive of recurrence, progression, and mortality in blad-
der cancer [34]. p53 overexpression was predictive of recur-
rence, progression, and mortality in 27%, 50%, and 29% of
eligible studies, respectively.
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Table 1: Single gene markers for prognosis and prediction of response in bladder cancer.
Markers Function Relation to bladder cancer
p5334 Tumor suppressor, DNA repair, and apoptosis p53 mutation associated with high recurrence and progression
ERCC141−43 DNA repair
Low expression associated with increased response to platinum-based
chemotherapy
RRM141, 49 Synthesis of deoxyribonucleotides
High expression with improved survival and possibly resistance to
gemcitabine
hENT154-55 Nucleoside transporter Sensitivity to gemcitabine
BRCA159 DNA repair Low expression related to increased response and prolonged survival
MDR142, 60 P-glycoprotein efflux pump High expression associated with resistance to chemotherapy
Bcl-264 Antiapoptosis protein Associated with more advanced stage and worse prognosis
In addition to having prognostic qualities, studies have
suggested that p53may be predictive of benefit to chemother-
apy [35]. A retrospective analysis of patients treated with ad-
juvant therapy found that patients with p53 alteration had
increased sensitivity to treatment and had more benefit
from adjuvant chemotherapy [36]. Since p53 is involved in
cell cycle arrest and DNA repair, the lack of a normal p53
could result in greater cancer cell killing when exposed to
DNA-damaging therapy. This hypothesis was put to the test
in a phase III trial that focused on patients with pT1 or
pT2, N0, M0 bladder cancer who had undergone a radical
cystectomy and bilateral pelvic lymphadenectomy [37]. This
group is not usually treated with adjuvant therapy but
has a recurrence rate of about 30%. Those whose tu-
mors demonstrated ≥ 10% nuclear immunoreactivity for
p53 were randomized to three cycles of adjuvant MVAC ver-
sus observation while p53-negative patients were observed.
The trial tried to confirm p53 as a predictive biomarker and
to see whether p53-altered tumors would respond better to
MVAC. A total of 521 patients were registered, 499 under-
went p53 assessment, 272 (55%) were positive, and 114
(42%) were randomly assigned. Unfortunately, due to the
high patient refusal rate, lower than expected event rate, and
failures to receive assigned therapy, accrual was halted and
questions about p53 as a biomarker remain.
4.1.2. ERCC1. Nucleotide excision repair pathway plays a
major role in DNA damage repair, and the excision repair
cross-complementing group 1 (ERCC1) is key member [38].
The cytotoxic effect of cisplatin is attributed to the formation
of bulky DNA adducts. ERCC1 helps remove these adducts
and thus may cause resistance to platinum agents [39]. In
NSCLC, high ERCC1 is associated with an improved prog-
nosis and predictive of reduced response to platinum-based
therapy [40].
Studies have also been done to evaluate ERCC1 as a bio-
marker in patients with advanced bladder cancer treated with
cisplatin-based chemotherapy. Bellmunt et al. performed
gene expression analysis by using real-time quantitative PCR
in tumors of 57 patients with metastatic or locally advanced,
surgically incurable patients who were treated with either
GC or GC plus paclitaxel [41]. At a median followup of
19 months, the median survival was significantly longer in
patients with low ERCC1 level (25.4 versus 15.4 months,
P = 0.03). Low ERCC1 level is predictive of the progression-
free survival in patients who received adjuvant cisplatin-
based chemotherapy. At 5 years, only 45% of patients with
low ERCC1 level had progressed versus 70% of patients with
high ERCC1 level (hazard ratio = 0.52, P = 0.03) [42]. There
was also a PFS advantage found in metastatic patients with
low ERCC1 (10.6 versus 8.4 months, P = 0.03) [43]. How-
ever, prospective randomized controlled clinical trials are
needed to determine the true value of ERCC1 expression in
predicting response to platinum-based chemotherapy.
4.1.3. RRM1. Ribonucleotide reductase subunit M1 (RRM1)
gene encodes one of two nonidentical subunits of ribonu-
cleotide reductase, an essential enzyme involved in the pro-
duction of deoxyribonucleotides for DNA synthesis and
repair [44]. Another function of RRM1 is suppression of cell
migration and metastasis formation [45]. It is the molecular
target of gemcitabine, an antimetabolite used in several ma-
lignancies including lung and bladder. Increased expression
of RRM1 is associated with increased survival of patients
with resected NSCLC [46]. In patients with early stage
NSCLC who had only received surgical treatment, the overall
survival for those with high RRM1 expression was more than
120 months compared to 60.2 months for those with low
RRM1 (P = 0.02) [47]. The survival advantage was limited to
patients with tumors that also expressed ERCC1. On the
other hand, high RRM1 expression appears to be a predictor
of decreased response to gemcitabine/platinum chemother-
apy [48].
RRM1 may have utility as a biomarker in bladder cancer
as well. In the Bellmunt study where patients received GC
with or without paclitaxel, there was a trend towards longer
time in progression in tumors with low RRM1 expression
[41]. High RRM1 expression was found to be prognostic for
improved survival in younger patients (aged < 70 years) with
muscle-invasive bladder [49]. The median overall survival
was 10.6 years in younger patients high RRM1 expression
versus 1.6 years in older patients (P = 0.001), but made no
significant difference for patients with low RRM1 expression
(2.3 versus 1.6 years in younger and older patients, resp.).
4.1.4. hENT1. Human equilibrative nucleoside transporter
1 (hENT1) is the major molecule of nucleoside transporter
proteins. Gemcitabine is a pyrimidine nucleoside analogue
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that requires plasma membrane nucleoside transporter pro-
teins to enter the cell and exert cytotoxicity. Studies in cul-
tured cells showed that hENT1 deficiency is associated with
gemcitabine resistance [50]. The ability for hENT1 to predict
benefit in patients receiving gemcitabine has been studied in
other cancers such as pancreas and lung [51–53].
In a small study of 12 patients, hENT1 was detected in 3
patients and two of them presented with a complete response
to gemcitabine [54]. The mean value of hENT1 was signifi-
cantly higher in the patients who had a pathological complete
response. A larger study evaluated 40 patients withmetastatic
bladder cancer who received GC-based chemotherapy [55].
Immunohistochemistry on tumor tissue was performed with
specific hENT1 antibodies. Eighteen (90%) out of 20 pa-
tients with high hENT1 expression showed a response to
chemotherapy whereas only 7 (35%) of 20 patients with low
hENT1 expression responded. A significantly longer median
survival was seen in patients with high hENT1 expression
than those with lower levels (17.3 versus 11.6 months, P =
0.003). Therefore, hENT1 might be a relevant biomarker in
metastatic bladder cancer patients receiving GC-based chem-
otherapy.
4.1.5. BRCA1. The breast cancer susceptibility gene 1
(BRCA1) is a tumor suppressor gene that is central in DNA
repair pathways. It encodes a nuclear protein that functions
in multiple biological processes, including gene transcrip-
tion, DNA damage repair, and apoptosis [56]. Low expres-
sion of BRCA1 has been found to increase sensitivity to
cisplatin-based chemotherapy in ovarian cancer and NSCLC
[57, 58]. A similar result was found in bladder cancer where
a significant pathologic response to neoadjuvant cisplatin-
based chemotherapy was attained in 66% of patients with
low/intermediate BRCA1 levels compared with 22% of
patients with high BRCA1 levels (P = 0.01) [59]. Median
survival was prolonged in patients with low/intermediate
compared to high BRCA1 levels (168 versus 34 months, P =
0.002). BRCA1 may be a useful tool in the selection of pa-
tients for neoadjuvant cisplatin-based chemotherapy.
4.1.6. MDR1. The multidrug resistance gene 1 (MDR1) en-
codes P-glycoprotein (Pgp), a membrane protein that acts as
an energy-dependent cellular efflux pump. Pgp can reduce
intracellular concentrations of chemotherapy drugs like an-
thracyclines and vinca alkaloids which are components of
MVAC, resulting in decreased cytotoxicity. Furthermore, it
appears that chemotherapy drugs induce MDR1 and lead to
drug resistance [60]. In patients with locally advanced blad-
der cancer receiving adjuvant chemotherapy, high MDR1
expression is associated with inferior survival [42]. After 2
years, more than 65% of patients with highMDR1 expression
had progressed compared to only 25% of patients with low
MDR1 expression. After 5 years, only 23% of patients with
high MDR1 expression were still alive versus 62% of patients
with low MDR1 expression (HR 0.25, P = 0.0006).
4.1.7. Bcl-2. B-cell lymphoma 2 (Bcl-2) is the represent-
ing member of the large Bcl-2 family that is important in
regulating cellular apoptosis. It was originally identified in
follicular lymphoma at the site of the t(14; 18) translocation
[61]. Bc1-2 is an antiapoptotic protein that is localized in in-
tracellular membranes and has been found to have prognos-
tic value in bladder cancer. Overexpression of Bcl-2 is asso-
ciated with reduced survival in patients with invasive bladder
cancer and lower response rate to chemotherapy [62]. In pa-
tients with invasive disease treated with radiotherapy only,
Bcl-2 positivity was found to be related to poor local control
(36 versus 72%) as well as to shorter disease-specific sur-
vival (74 versus 94%) at 3 years [63]. In a study of four apop-
tosis markers, including Bcl-2, caspase-3, p53, and survivin,
in patients treated by radical cystectomy, Bcl-2 was indepen-
dently associated with higher pathologic stage, probability of
disease recurrence (HR 2.24, P < 0.001), and disease-specific
mortality (HR 2.06, P = 0.001) [64].
4.1.8. MicroRNA. MicroRNA (miRNA) is small noncoding
regulatory RNA molecules with the stem-loop secondary
structure. Its size ranges from 17 to 25 nucleotides. It was
first found in worms but later was found in most eukaryotic
cells [65, 66]. It works as a posttranscriptional regulator of
genes by binding to the complementary 3′ untranslated re-
gion of target mRNA and degrading the target mRNA or sup-
pressing translation. Because one miRNA can bind to and
regulate the expression of multiple mRNAs, it works as
a master posttranscriptional regulator of gene expression.
miRNAs are involved in almost every aspects of oncogenesis.
They have been found to be upregulated or downregulated
depending on their corresponding functions as a tumor sup-
pressor or promoter [67]. Multiple miRNAs have been found
to be involved in bladder cancer [68]. Genome-wide deep se-
quencing of clinical specimens revealed that a set of miRNAs
was aberrantly expressed in bladder cancer when compared
to the normal matched control [69]. Many of the miRNA
dysregulated in bladder cancer were repeatedly identified in
other cancer types, but some of them have not been reported
before [70]. Some of these miRNAs affect several signaling
and metabolic pathways that can be potentially targeted for
cancer therapy in bladder cancer. Among those miRNAs,
MiR-34a is frequently downregulated or deleted in several
cancer types [71, 72]. It is a known downstream effector of
p53 that regulates several components of the p53 pathway
such as Cdk6 and E2F3. Researchers at University of Cali-
fornia at Davis found that transfection of bladder cancer cell
lines with pre-miR-34a followed by cisplatin treatment re-
sults in a dramatic reduction in clonogenic potential and in-
duction of senescence compared to treatment with cisplatin
alone. Analysis of 27 preneoadjuvant chemotherapy patient
samples revealed many of the patients who subsequently did
not respond to treatment (based on surgical resection post-
chemotherapy and 5-year survival data) express lower levels
of miR-34a [73]. However, the clinical significance needs to
be defined in prospective trials.
4.2. Combination of Genetic Markers. Individual gene bio-
markers may not adequately capture the complex molecular
activities in tumor cells. To accurately predict chemosen-
sitivity requires a large body of information. For example,
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there are over 150 genes involved in the major DNA repair
pathways that are relevant to platinum-DNA adducts alone.
Several studies have been conducted using a combination of
genetic markers to predict response to chemotherapy. Takata
et al. analyzed the gene expression profile of 27,648 genes
from 27 invasive bladder cancers using a cDNA microarray
[74]. Profiles of tumors from patients who responded to
MVAC neoadjuvant chemotherapy were compared to nonre-
sponders to develop a scoring system of 14 predictive genes.
This system was able to accurately predict drug response in
8 out of 9 patients. It was applied to 22 additional cases of
bladder cancer and correctly predicted clinical response for
19 cases [75]. Another approach uses the coexpression extra-
polation (COXEN) algorithm derived from expression mi-
croarray data of the National Cancer Institute (NCI)-60 cell
line panel to predict drug sensitivity of bladder cancer cell
lines [76]. The COXEN-based gene expression model was
able to effectively stratify chemosensitivity and predict the 3-
year overall survival in patients treated with MVAC [77].
4.3. DNA Damage as a Predictor of Chemoresistance. Thema-
jor limitation of studying individual genes or gene combina-
tion in cancer specimens is that in vivo patient pathophys-
iological changes cannot be analyzed. Furthermore, genetic
alterations can be so complicated that they cannot be fully
explored. For example, over 700 genes are involved in cellular
response to platinum chemotherapy [78]. Even though all
these genes can be studied with the currently available high
throughput analysis, such as microarray and whole genome
or transcriptome sequencing, the in vivo factors (such as drug
metabolism, distribution, local vasculature, and drug deliv-
ery) and external factors (such as dose calculation and ad-
ministration) cannot be analyzed.
To overcome these limitations, we have taken a radically
different approach to study chemoresistance to platinum
therapy in vivo under the physiological conditions [79, 80].
As alkylating agents, platinum analogs kill cancer cells mainly
through induction of DNA damage (adducts). We hypothe-
size that cancer cells with low platinum-induced DNA can
survive chemotherapy and are platinum resistant (Figure 1).
Therefore, measurement of platinum-induced DNA damage
may allow for identification of chemoresistance. By analyzing
some other major steps along the chemotherapy pathway,
such as drug metabolism and DNA repair, some of the major
underlying chemoresistant mechanisms can be determined
that help design of personalized chemotherapy to overcome
resistance. For example, if the chemoresistance to platinum
chemotherapy is secondary to increased DNA repair (as
measured by fast decrease of DNA adducts over time), plat-
inum drugs can be combined with a DNA repair inhibitor,
such as a PARP (Poly ADP ribose polymerase) inhibitor, to
overcome resistance. Several studies already showed that low
DNA damage induced by alkylating agents correlated with
chemoresistance with a few exceptions [81–90]. However, the
major limitation for those studies to be in clinical application
is that the technologies used in those studies are not sensitive
enough for clinical applications because patients had to
receive toxic therapeutic to high-dose chemotherapy before
DNA damage could be detected.
Platinum chemotherapy
Dose, administration
Drug metabolism
Drug delivery, local vasculature
Cell uptake and efflux
Intracellular inactivation
DNA damage
Cell cycle arrest and 
Fast repair/tolerance Slow repair/intolerance
Apoptosis/sensitive
DNA repair
Survival/resistance
Figure 1: Pathways leading to chemotherapy-induced cell death
and resistance. The major steps are shown in the sequential order.
DNA damage is the critical step in this response pathway. Cells with
low chemotherapy-induced DNA damage will survive chemother-
apy and are chemoresistant. We propose that chemoresistance can
possibly be identified by measuring chemotherapy-induced DNA
damage and that some of the underlying resistance mechanisms can
potentially be elucidated by measuring the other major steps such
as metabolism, cell uptake/efflux, and DNA repair. The underlined
steps can be determined with AMS.
We have developed a highly sensitive technology to meas-
ure carboplatin or oxaliplatin-induced DNA damage using
accelerator mass spectrometry (AMS). It is an isotope ratio
mass spectrometric method that precisely determines the
concentration of very rare (<1 : 109) isotope in an isolated
sample [91, 92]. Compared with the other technologies, the
advantage of using AMS to detect DNA adducts/damage is its
high sensitivity and precision. It can detect 14C at the zepto-
mole (zmole, 10−21 mole) level per mg of carbon with the
precision as low as 0.25% [93]. To measure platinum-in-
duced DNA damage, 14C-labeled platinum analogs are used.
When DNA damage is induced, platinum analogs together
with 14C are conjugated to genomic DNA. By measuring the
amount of 14C on genomic DNA, the amount of DNA da-
mage can be calculated. Because of the supersensitivity of
AMS, this approach allows themeasurement of DNA adducts
without exposing cancer cells or patients to toxic chemother-
apy. To perform this test, cancer cells/patients are first treated
with one nontoxicmicrodose (1% of therapeutic dose or less)
of 14C-labeled platinum drug before cancer patients undergo
biopsy or surgical resection. Biopsy is required for most can-
cer patients before chemotherapy can be administered as the
standard of care. Some of the tumor specimens will be used
for the AMS analysis. Only a few milligrams of tumor tissue
are needed for detection of DNA adducts with AMS. One
major limitation of this approach is that cisplatin cannot
be studied as there is no carbon atom in cisplatin molecule
to allow for 14C labeling. Fortunately, the chemoresistance
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spectrum of cisplatin and carboplatin is very similar as these
two drugs form the same platinum-DNA cross-links [94].
We have performed extensive preclinical studies to show
the feasibility of this microdosing approach [79, 80, 95].
Microdosing with 14C-carboplatin could induce DNA dam-
age, the physiological target of therapeutic carboplatin. The
DNA damage induced by microdosing is highly linearly pro-
portional to that of therapeutic carboplatin (P < 10−15), sug-
gesting that the microdosing approach can be used to predict
DNA damage induced by therapeutic dose of carboplatin. In
studies with cell lines, the level of DNA damage is superior
in predicting chemoresistance when compared to the ERCC1
level [80]. This finding is consistent with the underlying pa-
thophysiology of resistance to platinum in that ERCC1 is one
of many proteins involved in DNA repair while DNA damage
levels are the cumulative results of formation and repair of
DNA damage. Because carboplatin is rarely used in clinic as
a single agent, we determined and found that addition of
gemcitabine had little effects on the formation of platinum-
DNA adducts in a bladder cancer cell line [95]. Based on
these preclinical studies, a Phase 0 microdosing trial has been
designed and is currently going on to determine if the DNA
damage induced by the microdosing 14C-carboplatin corre-
late with chemotherapy outcomes (http://clinicaltrials.gov/
identifier no. NCT01261299).
5. Conclusion
Cancer therapeutics is moving towards personalized medi-
cine to select the most effective therapy while avoiding the
ineffective and/or toxic therapy based on the underlying pa-
thophysiology of the patients and their tumors. In bladder
cancer, questions remain about who will benefit most from
chemotherapy as only around 50% of bladder cancer patients
will have tumor response from chemotherapy. Biomarkers
have shown promise in prognostication and in selecting ther-
apy and might help answer some of these questions. For ex-
ample, ERCC1 status may be important to be determined be-
fore giving platinum-based chemotherapy, or hENT1 or
RRM1 before gemcitabine. Combinations of biomarkers (in-
cluding microRNA) can offer more accuracy in prediction
than individual ones. Our group is using a microdosing ap-
proach to identify resistance to platinum drugs [79, 80]. The
efficacy needs to be determined in large clinical trials. A
better understanding of tumor biology and pathogenic path-
ways will hopefully lead to more molecularly targeted ther-
apy. Research is ongoing to test agents that target the fibrob-
last, epidermal, and vascular endothelial growth factor path-
ways [96]. The hope is that in the future targeted therapy will
augment cytotoxic chemotherapy and that biomarkers will
be able to risk stratify patients and help optimize therapy.
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